Sheehan Katherine M, O'Connell Fionnuala, O'Grady Anthony, Conroy Ronan M, Leader Mary B, Byrne Michael F, Murray Frank E, Kay Elaine W
Department of Pathology, Epidemiology and Clinical Pharmacology, Royal College of Surgeons in Ireland, Beaumont Hospital, Dublin, Ireland.
Eur J Gastroenterol Hepatol. 2004 Jun;16(6):619-25. doi: 10.1097/00042737-200406000-00017.
Cyclooxygenase 2 (COX-2) is a target of aspirin and other non-steroidal anti-inflammatory drugs and is implicated in the pathogenesis of colorectal cancer. The objective of this study was to evaluate the extent of COX-2 in pre-malignant colorectal polyps and to assess the relationship between COX-2 and the level of dysplasia in these lesions.
Whole polypectomy specimens were retrieved from 123 patients by endoscopic or surgical resection. Following formalin fixation and paraffin embedding, the polyps were evaluated histologically for size, type and grade of dysplasia. The extent of COX-2 expression was measured by the avidin-biotin immunohistochemical technique using a monoclonal COX-2 antibody. The extent of COX-2 expression was graded according to percentage epithelial COX-2 expression.
The polyps were of the following histological types: 10 hyperplastic, 35 tubular adenomas, 61 tubulovillous adenomas and 17 villous adenomas. Twenty showed mild dysplasia, 65 moderate dysplasia, and 28 focal or severe dysplasia (including eight with focal invasion). The average polyp size was 1.7 cm. Nine hyperplastic polyps were COX-2-negative and one was COX-2-positive. COX-2 expression was more extensive in larger polyps and in polyps with a higher villous component. There was a significant increase in the extent of COX-2 protein with increasing severity of dysplasia. Within a polyp, there was a focal corresponding increase in COX-2 expression within epithelium showing a higher grade of dysplasia.
COX-2 expression is related directly to colorectal adenomatous polyp size, type and grade of dysplasia. This suggests that the role of COX-2 in colorectal cancer may be at an early stage in the adenoma-to-carcinoma sequence and supports the suggestion that inhibition of COX-2 may be useful chemoprevention for this disease.
环氧化酶2(COX - 2)是阿司匹林和其他非甾体抗炎药的作用靶点,与结直肠癌的发病机制有关。本研究的目的是评估COX - 2在结直肠癌前息肉中的表达程度,并评估COX - 2与这些病变中发育异常程度之间的关系。
通过内镜或手术切除从123例患者中获取完整的息肉切除标本。经福尔马林固定和石蜡包埋后,对息肉进行组织学评估,包括发育异常的大小、类型和分级。使用单克隆COX - 2抗体,通过抗生物素蛋白 - 生物素免疫组织化学技术测量COX - 2表达程度。根据上皮COX - 2表达百分比对COX - 2表达程度进行分级。
息肉的组织学类型如下:10例增生性息肉、35例管状腺瘤、61例管状绒毛状腺瘤和和17例绒毛状腺瘤。20例显示轻度发育异常,65例中度发育异常,28例局灶性或重度发育异常(包括8例伴有局灶性浸润)。息肉平均大小为1.7厘米。9例增生性息肉COX - 2阴性,1例COX - 2阳性。COX - 2在较大息肉和具有较高绒毛成分的息肉中表达更广泛。随着发育异常严重程度的增加,COX - 2蛋白表达程度显著增加。在息肉内,发育异常程度较高的上皮内COX - 2表达有相应的局灶性增加。
COX - 2表达与结直肠腺瘤性息肉大小、类型及发育异常分级直接相关。这表明COX - 2在结直肠癌中的作用可能处于腺瘤 - 癌序列的早期阶段,并支持COX - 2抑制可能是该病有效化学预防措施的观点。